| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
PLGA‑PEG‑MAL does not have a specific biological receptor target but serves as a drug delivery vehicle. The maleimide (MAL) group reacts specifically with thiol groups (-SH) on proteins, peptides, or other thiol‑containing molecules to form stable thioether bonds. The PLGA block provides biodegradability and controlled release properties, while the PEG block provides water solubility, biocompatibility, and reduced non‑specific protein adsorption.
|
|---|---|
| ln Vitro |
In vitro, PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) is used to prepare mucoadhesive nanoparticles for drug delivery applications. The maleimide functional group enables the conjugation of thiolated ligands or therapeutic agents to the nanoparticle surface. The PLGA‑PEG‑MAL nanoparticles have been studied as carriers for intravesical drug delivery.
|
| ln Vivo |
In vivo, PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25)‑containing nanoparticles can be used for targeted drug delivery. The PEG component reduces opsonization and prolongs circulation time, while the maleimide group enables the attachment of targeting moieties for specific delivery to tissues or cells of interest. The PLGA component provides controlled release of encapsulated drugs.
|
| Enzyme Assay |
Non‑cellular assays for PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) typically involve demonstrating its ability to react with thiol‑containing molecules. The polymer can be incubated with a thiol‑functionalized molecule (e.g., a cysteine‑containing peptide), and the formation of the conjugation product can be confirmed by techniques such as mass spectrometry, gel electrophoresis, or NMR spectroscopy. The polymer's ability to form nanoparticles can be assessed by dynamic light scattering (DLS) and electron microscopy.
|
| Cell Assay |
In vitro cellular assays for PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) involve treating cells with the polymer or polymer‑based nanoparticles to assess cellular uptake, cytotoxicity, and targeting efficiency. The polymer itself is a delivery vehicle and does not have direct biological activity on cells. Cellular uptake of fluorescently labeled nanoparticles can be quantified by flow cytometry or fluorescence microscopy. Cytotoxicity is assessed using standard assays such as MTT.
|
| Animal Protocol |
In vivo animal experiments for PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) would involve administering the polymer or polymer‑based nanoparticles to animal models to evaluate biodistribution, pharmacokinetics, and therapeutic efficacy. The polymer has been studied as a mucoadhesive carrier for intravesical drug delivery. Endpoints would include tissue distribution, drug release kinetics, and therapeutic outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) are influenced by the properties of the nanoparticles formed from the polymer. The PEG component prolongs circulation time by reducing opsonization and clearance by the reticuloendothelial system. The PLGA component provides controlled drug release. The maleimide group itself does not significantly affect the PK profile. The polymer should be stored under recommended conditions as per the Certificate of Analysis.
|
| Toxicity/Toxicokinetics |
Toxicological data for PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) are limited. PLGA and PEG are biocompatible and biodegradable polymers that are widely used in FDA‑approved drug delivery systems. The maleimide group is reactive but is typically consumed during conjugation and is present at low concentrations in the final formulation. Standard safety precautions for handling polymer reagents apply.
|
| References |
|
| Additional Infomation |
PLGA‑PEG‑MAL (60kDA‑3.4kDA, LA:GA ratio 75:25) is a PLGA‑PEG‑Mal nanoparticle comprising poly(lactic‑co‑glycolic acid) and polyethylene glycol blocks. Its molecular weight is 60kDA‑3.4kDA, with a composition ratio of lactic acid (LA) to glycolic acid (GA) molecules at 75:25. It is used as a mucoadhesive carrier for drug delivery applications. It is supplied for research purposes only.
|
| Related CAS # |
PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
